Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 881 | 1,238 | 1,361 | 1,148 | 1,185 | 1,195 | 1,745 | 1,236 |
| Operating profit | €m | 305 | 276 | ||||||
| Net profit | €m | 248 | 311 | 241 | 160 | 188 | 156 | 211 | 205 |
| EPS reported | € | 2.76 | 3.21 | ||||||
| Operating cashflow per share | € | 6.13 | 8.58 | ||||||
| Capex per share | € | 2.46 | 1.24 | ||||||
| FCF per share | € | 3.67 | 7.34 | ||||||
| Free cash flow | €m | 205 | 411 | ||||||
| Net debt | €m | 512 | 769 | ||||||
| Book value equity | €m | 1,584 | 1,423 | ||||||
| Book value per share | € | 28.32 | 25.44 | ||||||
| Number of shares | m | 55.95 | 55.95 | ||||||
| DPS (TTM paid) | € | 1.30 | 1.30 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 24.86 | 24.12 | ||||||
| P/B LTM | x | 2.42 | 2.69 | ||||||
| P/S LTM | x | 3.21 | 2.19 | ||||||
| P/FCF LTM | x | 18.72 | 9.32 | ||||||
| EV/EBITDA LTM | x | 10.32 | 8.55 | ||||||
| EV/Sales LTM | x | 3.74 | 2.64 | ||||||
| Earnings Yield LTM | % | 4.02% | 4.15% | ||||||
| FCF Yield | % | 5.34% | 10.73% | ||||||
| Quality | |||||||||
| ROE | % | 9.82% | 13.91% | ||||||
| ROIC | % | 8.23% | 7.51% | ||||||
| Operating margin | % | 25.49% | 15.82% | ||||||
| Gross margin | % | 58.57% | 64.48% | ||||||
| FCF/Sales | % | 17.16% | 23.55% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -18.10% | -25.69% | ||||||
| Sales Growth YoY | % | +0.84% | +43.57% | ||||||
| Net Income Growth YoY | % | -17.27% | +10.32% | ||||||
| FCF Growth | % | -14.22% | +27.09% | ||||||
| Operating Profit Growth | % | +17.90% | -36.80% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.65% | 1.68% | ||||||
| Dividend Growth | % | +8.33% | +8.33% | ||||||
| Payout Ratio | % | 41.15% | 36.86% | ||||||
| FCF/Debt | x | 0.26 | 0.43 | ||||||
| Net Debt/EBITDA | x | 1.44 | 1.56 | ||||||
| EBIT/Net interest | x | 12.44 | 12.20 | ||||||
| Net debt/market cap | % | 13.34% | 20.09% | ||||||
| Net debt/Equity | x | 0.32 | 0.54 | ||||||
| Gross debt/equity | x | 0.50 | 0.67 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free